Surrozen (SRZN) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Surrozen (SRZN) overview

Surrozen (SRZN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3.5m and operating profit of USD -42.1m; the year-end share price was 22.60 USD and market capitalisation was USD 221m. Surrozen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Surrozen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -188mFY 2025
Share price22.60 USDFY 2025 year end
RevenueUSD 3.5mFY 2025
Operating profitUSD -42.1mFY 2025
Net earningsUSD -242mFY 2025
Market capitalisationUSD 221mFY 2025 year end

About Surrozen

Surrozen is a biotechnology company developing therapies that modulate the Wnt pathway, with current development focused on ophthalmology. Its product candidates are antibody-based therapeutics designed to affect Wnt signaling in eye diseases. The company is developing SZN-8141 and SZN-8143 for retinal conditions, while evaluating research programs in other ophthalmic indications. It has licensed SZN-413 to Boehringer Ingelheim for research, development, and commercialization.

Generate the Surrozen report

Surrozen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Surrozen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Surrozen

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.